MADRID — For patients with advanced melanoma that is BRAF-mutation positive, the combination of a BRAF and MEK inhibitor works better than a BRAF inhibitor alone. The data come from 2 phase 3 trials ...
A report reviews the case of a patient with stage IV melanoma who, while having several issues with treatment toxicity, was later free of disease following treatment with BRAF and MEK inhibitors. BRAF ...
Combination CDK4/6 and MEK inhibitor treatment reduced tumor growth in mouse models of melanoma with acquired resistance to BRAF and MEK inhibition. A preclinical study published in Molecular Cancer ...
Melanoma has long been one of oncology’s most instructive adversaries. Roughly half of all melanomas are driven by mutations ...
BRAF and MEK inhibitors are effective in treating resectable melanoma with BRAF V600 mutations, achieving significant pathological responses. The combination therapy significantly improves ...
Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E–mutated non–small cell lung cancer. First-line immune checkpoint inhibitors (ICIs) with or ...
Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies Issued: 29 ...
Deeper inhibition of the MAPK pathway by targeting both MEK and BRAF may help improve progression-free survival outcomes in patients with advanced BRAF V600–mutated melanoma. Deeper inhibition of the ...
A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain ...
Single-agent BRAF-inhibitor therapy has a proven survival benefit for patients with advanced-stage melanoma and is approved for this indication; however, downsides of this approach are early acquired ...
Please provide your email address to receive an email when new articles are posted on . Most patients treated with BRAF and MEK inhibitors for histiocytic disorders showed no active disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results